8-K: Akebia Therapeutics Reports Q2 2024 Results, Vafseo Launch on Track

Akebia Therapeutics announced its second quarter 2024 financial results, highlighted by progress in the commercial launch of Vafseo and Auryxia revenue updates.

Summary

• Akebia Therapeutics reported a net loss of $8.6 million for the second quarter of 2024, an improvement from the $11.2 million loss in the same period last year.
• Total revenue for the quarter was $43.6 million, down from $56.4 million in Q2 2023, primarily due to a decrease in license and collaboration revenue.
• Net product revenue was $41.2 million, slightly down from $42.2 million in the second quarter of 2023.
• The company's cash and cash equivalents stood at $39.5 million as of June 30, 2024.
• Akebia expects its current cash resources and cash from operations to fund its operations, including the Vafseo launch, for at least two years.
• Vafseo's market availability is on track for January 2025, with a wholesale acquisition cost (WAC) set at $1,278 for a 30-day supply, or approximately $15,500 per year.
• The company submitted its Transitional Drug Add-on Payment Adjustment (TDAPA) application in June and expects TDAPA designation by January 1, 2025.
• Akebia regained full rights to sell Vafseo in the U.S. after a royalty-based termination agreement with CSL Vifor.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in the Vafseo launch, improved net loss, and sufficient cash runway. However, the decrease in total revenue and slight decrease in Auryxia revenue temper the overall optimism.

Positives

• Akebia's net loss improved to $8.6 million in Q2 2024 from $11.2 million in Q2 2023.
• The Vafseo launch is on track for January 2025, with key steps like TDAPA application submission completed.
• Akebia has regained full U.S. rights to Vafseo, simplifying operations and improving economics.
• The company's cash position is expected to support operations for at least two years.
• Auryxia revenues remain relatively stable, with full-year expectations in line with 2023.

Negatives

• Total revenue decreased to $43.6 million in Q2 2024 from $56.4 million in Q2 2023, primarily due to a reduction in license and collaboration revenue.
• Net product revenues for Auryxia slightly decreased to $41.2 million in Q2 2024 from $42.2 million in Q2 2023.
• The company reported a net loss of $8.6 million for the quarter.

Risks

• The commercial success of Vafseo is subject to market acceptance, coverage, and reimbursement.
• The company faces competition from other treatments for anemia in dialysis patients.
• There are risks associated with manufacturing, supply chain, and quality control.
• The company's future performance is subject to regulatory decisions and potential changes in healthcare policies.
• There are risks associated with the potential for early termination of collaborations.

Future Outlook

Akebia expects its existing cash resources and cash from operations will be sufficient to fund its current operating plan, including the U.S. Vafseo launch, for at least two years. The company anticipates Vafseo market availability in January 2025 and expects Auryxia full year 2024 net product revenues to be in line with 2023 levels.

Management Comments

• John P. Butler, Chief Executive Officer of Akebia, stated that the company is actively engaged with prescribers and is encouraged by the positive reception for Vafseo.
• John P. Butler also noted that the commercial team is in active discussions with dialysis organizations to contract both Auryxia and Vafseo.

Industry Context

This announcement comes as Akebia is preparing to launch Vafseo, a new treatment for anemia in dialysis patients, in a market that is currently dominated by erythropoietin stimulating agents (ESAs). The company is also navigating changes in the reimbursement landscape with the expected inclusion of phosphate binders in the Centers for Medicare & Medicaid Services bundled payment for dialysis care in January 2025.

Comparison to Industry Standards

• Akebia's Q2 2024 revenue of $43.6 million is lower than the $56.4 million reported in Q2 2023, primarily due to a decrease in license and collaboration revenue. This is a common trend for companies transitioning from development to commercialization, as upfront payments from collaborations decrease.
• The company's net loss of $8.6 million is an improvement compared to the $11.2 million loss in the same period last year, indicating progress in cost management.
• The launch of Vafseo is a key milestone for Akebia, and its success will be measured against existing treatments for anemia in dialysis patients, such as ESAs and other HIF-PH inhibitors. Companies like FibroGen and GSK are also developing similar treatments, making the market competitive.
• Akebia's Auryxia revenue of $41.2 million is relatively stable, but the company will need to secure contracts with dialysis organizations to maintain this revenue stream, especially with the expected changes in reimbursement in 2025.
• The company's cash position of $39.5 million is sufficient to fund operations for at least two years, which is a positive sign for investors. However, the company will need to manage its cash burn carefully as it ramps up the Vafseo launch.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and the success of the Vafseo launch.
• Employees will be involved in the commercialization efforts for Vafseo and the ongoing operations of the company.
• Patients with chronic kidney disease will benefit from the availability of Vafseo as a new treatment option.
• Dialysis organizations will be key partners in the commercialization of Vafseo and Auryxia.
• Creditors will be impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• Akebia will continue to engage with prescribers and dialysis organizations to secure contracts for Vafseo and Auryxia.
• The company will focus on the commercial launch of Vafseo in the U.S. market.
• Akebia will monitor the regulatory landscape and reimbursement policies.
• The company will continue to manage its operating expenses and cash burn.

Key Dates

Keywords

Vafseo, vadadustat, Auryxia, ferric citrate, anemia, chronic kidney disease, CKD, dialysis, TDAPA, HCPCS, biopharmaceutical, renal, healthcare